

PENDING CLAIMS

Please cancel claims 24-28 without prejudice.

Please add new claims 29 and 30 as indicated below.

A complete list of claims as currently amended follows:

1. (previously presented) A multi-layered pharmaceutical dosage form comprising:
 - a. at least one proton pump inhibitor layer comprising a proton pump inhibitor granule, and an additional pharmaceutical excipient wherein the proton pump inhibitor granule comprises (i) a proton pump inhibitor and (ii) a film forming water insoluble polymer, a congeable solid material or a combination of a film forming water insoluble polymer and a congeable solid material and wherein the proton pump inhibitor layer is free of acidic film forming polymers and enteric polymers; and
 - b. at least one antacid layer comprising an aluminum, magnesium or calcium antacid salt and a pharmaceutically acceptable excipient, wherein the proton pump inhibitor layer and the antacid layer are distinct from each other and the multi-layered pharmaceutical dosage form is free of sodium bicarbonate.
2. (original) The pharmaceutical dosage form as defined in claim 1 that comprises at least two antacid layers.
3. (original) The pharmaceutical dosage form as defined in claim 1 wherein the dosage form is a compressed tablet.
4. (original) The pharmaceutical dosage form as defined in claim 1 wherein the dosage form is a capsule.
5. (original) The pharmaceutical dosage form as defined in claim 3 wherein the tablet is chewable.
6. (original) The pharmaceutical dosage form as defined in claim 3 wherein the tablet is rapidly disintegrating.
7. (original) The pharmaceutical dosage form as defined in claim 4 wherein the capsule is rapidly disintegrating.

8. (previously presented) The pharmaceutical dosage form as defined in claim 1 wherein the proton pump inhibitor layer further comprises an alkaline amino compound.
9. (previously presented) The pharmaceutical dosage form as defined in claim 8 wherein the alkaline amino compound is arginine or lysine.
10. (original) The pharmaceutical dosage form as defined in claim 1 wherein the proton pump inhibitor is omeprazole, lansoprazole, pantoprazole, pariprazole, leminoprazole, salts, isomers, or derivatives thereof.
11. (original) The pharmaceutical dosage form as defined in claim 1 wherein the antacid salts are aluminum or calcium salts of hydroxides, carbonates, sulfates, bicarbonates, or silicates.
12. (original) The pharmaceutical dosage form as defined in claim 11 wherein the antacid salts are aluminum or calcium salts of hydroxides, carbonates, sulfates, or silicates.
13. (canceled).
14. (canceled).
15. (previously presented) The pharmaceutical dosage form as defined in claim 1 wherein the congealable solid material is a wax.
16. (previously presented) The pharmaceutical dosage form as defined in claim 1 wherein the congealable solid material is glyceryl monostearate or castor oil.
17. (canceled).
18. (canceled).
19. (original) The pharmaceutical dosage form as defined in claim 1 wherein the antacid layer further comprises granules that comprise an antacid and a binder.
20. (original) The pharmaceutical dosage form as defined in claim 19 wherein the antacid layer further comprises a taste masking agent.
21. (original) The pharmaceutical dosage form as defined in claim 19 wherein the granules are prepared by a dry granulation technique.
22. (previously presented) The pharmaceutical dosage form as defined in claim 19 wherein the granules are prepared by roller compaction.

23. (original) The pharmaceutical dosage form as defined in claim 19 wherein the granules are prepared by a wet granulation technique.

24-28 (canceled).

29. (new) A bilayered pharmaceutical dosage form consisting of:

- a. an omeprazole layer comprising an omeprazole granule and an additional pharmaceutical excipient wherein the omeprazole granule comprises (i) omeprazole and (ii) a film forming water insoluble polymer, a congeable solid material or a combination of a film forming water insoluble polymer and a congeable solid material and wherein the omeprazole layer is free of acidic film forming polymers and enteric polymers; and
- b. an antacid layer comprising an aluminum, magnesium or calcium antacid salt and a pharmaceutically acceptable excipient, wherein the omeprazole layer and the antacid layer are distinct from each other and the bilayered pharmaceutical dosage form is free of sodium bicarbonate.

30. (new) A trilayered pharmaceutical dosage form consisting of:

- a. an omeprazole layer comprising an omeprazole granule and an additional pharmaceutical excipient wherein the omeprazole granule comprises (i) omeprazole and (ii) a film forming water insoluble polymer, a congeable solid material or a combination of a film forming water insoluble polymer and a congeable solid material and wherein the omeprazole layer is free of acidic film forming polymers and enteric polymers; and
- b. two antacid layers comprising an aluminum, magnesium or calcium antacid salt and a pharmaceutically acceptable excipient, wherein the omeprazole layer is between the two antacid layers and the trilayered pharmaceutical dosage form is free of sodium bicarbonate.